secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-04-16T23:59:59+00:00
Accession:  0001641172-25-004971
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharma: Ketamir-2 shows positive preclinical results in diabetic neuropathy rat model
--------------------------------------------------------------------------------

- Ketamir-2 significantly reduced neuropathic pain in a rat model of type 2 diabetes (high-fat diet + STZ).
- Some treated animals returned to pre-diabetic baseline sensitivity, indicating full symptom reversal.
- Results confirm oral bioavailability and non-dissociative profile, supporting ongoing Phase I trial in healthy volunteers.
- Company plans to initiate Phase IIa trial in diabetic neuropathy patients by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225004971/0001641172-25-004971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225004971/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-004971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer